vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $188.3M, roughly 1.3× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 11.1%, a 36.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -21.9%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -15.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $188.3M |
| Net Profit | $27.5M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 14.1% | 32.3% |
| Net Margin | 11.1% | 47.9% |
| Revenue YoY | 29.6% | -21.9% |
| Net Profit YoY | 367.5% | 1710.8% |
| EPS (diluted) | $1.14 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $188.3M | ||
| Q3 25 | $227.8M | $215.3M | ||
| Q2 25 | $211.4M | $188.2M | ||
| Q1 25 | $197.1M | $197.2M | ||
| Q4 24 | $190.6M | $241.0M | ||
| Q3 24 | $148.3M | $225.5M | ||
| Q2 24 | $138.0M | $256.0M | ||
| Q1 24 | $137.4M | $263.4M |
| Q4 25 | $27.5M | $90.3M | ||
| Q3 25 | $26.6M | $91.1M | ||
| Q2 25 | $8.5M | $139.5M | ||
| Q1 25 | $15.7M | $-10.0M | ||
| Q4 24 | $-10.3M | $-5.6M | ||
| Q3 24 | $-24.2M | $-284.4M | ||
| Q2 24 | $-2.3M | $-433.6M | ||
| Q1 24 | $18.2M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | 14.1% | 32.3% | ||
| Q3 25 | 15.9% | 30.4% | ||
| Q2 25 | 6.6% | 5.7% | ||
| Q1 25 | 13.3% | -31.2% | ||
| Q4 24 | -2.3% | -69.2% | ||
| Q3 24 | -13.8% | -36.4% | ||
| Q2 24 | 3.7% | -90.8% | ||
| Q1 24 | 14.8% | -6.1% |
| Q4 25 | 11.1% | 47.9% | ||
| Q3 25 | 11.7% | 42.3% | ||
| Q2 25 | 4.0% | 74.1% | ||
| Q1 25 | 8.0% | -5.1% | ||
| Q4 24 | -5.4% | -2.3% | ||
| Q3 24 | -16.3% | -126.1% | ||
| Q2 24 | -1.7% | -169.4% | ||
| Q1 24 | 13.2% | -18.7% |
| Q4 25 | $1.14 | $2.78 | ||
| Q3 25 | $1.13 | $2.91 | ||
| Q2 25 | $0.36 | $4.50 | ||
| Q1 25 | $0.69 | $-0.39 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $-1.27 | $-9.39 | ||
| Q2 24 | $-0.14 | $-14.35 | ||
| Q1 24 | $0.82 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $540.7M | $-171.5M |
| Total Assets | $1.4B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $226.6M | ||
| Q3 25 | $262.6M | $184.2M | ||
| Q2 25 | $217.8M | $267.4M | ||
| Q1 25 | $149.8M | $138.3M | ||
| Q4 24 | $144.9M | $146.9M | ||
| Q3 24 | $145.0M | $159.2M | ||
| Q2 24 | $240.1M | $236.9M | ||
| Q1 24 | $228.6M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $-171.5M | ||
| Q3 25 | $505.8M | $-260.5M | ||
| Q2 25 | $436.8M | $-351.7M | ||
| Q1 25 | $418.6M | $-496.8M | ||
| Q4 24 | $403.7M | $-488.2M | ||
| Q3 24 | $405.9M | $-497.6M | ||
| Q2 24 | $455.8M | $-218.3M | ||
| Q1 24 | $452.0M | $228.4M |
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $920.8M | $3.2B | ||
| Q1 24 | $914.5M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $26.2M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $26.2M | ||
| Q3 25 | $44.1M | $-60.6M | ||
| Q2 25 | $75.8M | $-25.6M | ||
| Q1 25 | $35.0M | $184.0K | ||
| Q4 24 | $15.9M | $-2.7M | ||
| Q3 24 | $12.5M | $19.5M | ||
| Q2 24 | $17.4M | $111.5M | ||
| Q1 24 | $18.3M | $135.4M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 0.29× | ||
| Q3 25 | 1.66× | -0.66× | ||
| Q2 25 | 8.87× | -0.18× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
